Kailera Therapeutics
Last verified 2026-05-23. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $600.0Mattributed |
|---|---|
| Latest round | series-b, $600.0M, 2025-10-01attributed |
| Founded | 2023 |
| Headquarters | San Diego, US |
| Industry | bio |
| Stage | series-b+ |
| Website | kailera.com |
Kailera Therapeutics is a clinical-stage biotech advancing GLP-1, GIP, and amylin agonist drug candidates for obesity. The customer base is patients with chronic weight-related metabolic disease. Backed by Bain Capital Life Sciences and others, Kailera ran a Phase 3 program for KAI-9531 in adults with obesity.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-b | $600.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Magnific Popup, Yoast SEO 27.4, reCAPTCHA, Google Analytics, Google Tag Manager, FitVids.JS 1778785549, Font Awesome, ScrollMagic 2.0.7, jQuery Migrate, jQuery Mobile
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $600.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $600.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | kailera.com, read 2026-05-23 |
| Description | self-reported | kailera.com, read 2026-05-23 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.